46.30
전일 마감가:
$45.66
열려 있는:
$45.61
하루 거래량:
1.51M
Relative Volume:
0.50
시가총액:
$8.79B
수익:
$217.77M
순이익/손실:
$-438.86M
주가수익비율:
-19.21
EPS:
-2.41
순현금흐름:
$-456.33M
1주 성능:
-0.45%
1개월 성능:
+4.33%
6개월 성능:
+23.17%
1년 성능:
+73.41%
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
BBIO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BBIO
Bridgebio Pharma Inc
|
46.30 | 8.67B | 217.77M | -438.86M | -456.33M | -2.41 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-21 | 개시 | Truist | Buy |
2025-07-14 | 개시 | Jefferies | Buy |
2025-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
2025-06-17 | 개시 | Wolfe Research | Outperform |
2025-03-31 | 개시 | Redburn Atlantic | Buy |
2024-10-16 | 개시 | Scotiabank | Sector Outperform |
2024-10-03 | 개시 | Oppenheimer | Perform |
2024-09-04 | 개시 | Piper Sandler | Overweight |
2024-03-21 | 재개 | Raymond James | Outperform |
2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
2023-12-08 | 개시 | Wells Fargo | Overweight |
2023-11-07 | 개시 | Citigroup | Buy |
2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
2023-04-19 | 개시 | Evercore ISI | Outperform |
2023-02-06 | 개시 | Cowen | Outperform |
2021-12-27 | 재확인 | Mizuho | Buy |
2021-12-27 | 재확인 | SVB Leerink | Outperform |
2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
2021-05-21 | 개시 | UBS | Buy |
2021-03-22 | 재확인 | Goldman | Buy |
2021-02-22 | 재개 | JP Morgan | Overweight |
2021-02-09 | 재개 | Goldman | Buy |
2021-01-11 | 재확인 | H.C. Wainwright | Buy |
2020-12-10 | 재확인 | H.C. Wainwright | Buy |
2020-06-25 | 개시 | BofA/Merrill | Neutral |
2020-05-19 | 개시 | BTIG Research | Buy |
2020-04-13 | 개시 | H.C. Wainwright | Buy |
2020-02-19 | 개시 | Mizuho | Buy |
2019-07-26 | 개시 | Raymond James | Outperform |
2019-07-22 | 개시 | BMO Capital Markets | Outperform |
2019-07-22 | 개시 | Goldman | Buy |
2019-07-22 | 개시 | JP Morgan | Overweight |
2019-07-22 | 개시 | Jefferies | Buy |
2019-07-22 | 개시 | Piper Jaffray | Overweight |
2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
What are the latest earnings results for BridgeBio Pharma Inc.Massive portfolio appreciation - jammulinksnews.com
Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT - MSN
Why BridgeBio Pharma Inc. stock attracts strong analyst attentionMassive Profit Potential - Metal.it
Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy - MSN
Will BridgeBio Pharma Inc. stock benefit from interest rate changesFree Stock Market Forecasting Tools - Metal.it
Why BridgeBio Pharma Inc. stock is on top investor watchlistsMarket-leading growth rates - jammulinksnews.com
What drives BridgeBio Pharma Inc. stock priceFree Stock Market Query - PrintWeekIndia
Bridgebio Pharma shares rise 1.97% premarket after novel human genetics evidence confirms estimates of genetic prevalence and underdiagnosis of ADH1. - AInvest
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen - Insider Monkey
Groundbreaking Genetics Study Uncovers 25,000 Hidden ADH1 Cases in US and EU, Most Patients Undiagnosed - Stock Titan
BridgeBio Pharma Inc. Stock Analysis and ForecastConsistently profitable trades - jammulinksnews.com
Is BridgeBio Pharma Inc. a good long term investmentOutstanding risk-reward balance - jammulinksnews.com
What analysts say about BridgeBio Pharma Inc. stockRobust investment performance - jammulinksnews.com
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET - The Manila Times
BridgeBio Pharma, Inc. Scheduled to Release Q2 Financial Results and Business Updates on August 5, 2025 - Nasdaq
BridgeBio, Genetic Disease Pioneer, Sets Q2 2025 Earnings Release DateKey Details Inside - Stock Titan
Truist Securities Initiates Coverage on BridgeBio Pharma with 'Buy' Rating and $66 Price Target - AInvest
BridgeBio Pharma Stock (BBIO) Opinions on Analyst Buy Ratings and Attruby Launch - Quiver Quantitative
BridgeBio stock initiated with Buy rating at Truist on strong Attruby launch - Investing.com Canada
BridgeBio Pharma (BBIO) Receives New 'Buy' Rating from Truist Se - GuruFocus
BridgeBio Pharma stock maintains Buy rating at H.C. Wainwright after royalty deal - Investing.com Canada
These 2 Momentum Stocks Got a Bullish Nod — Here’s Why They Could Reach New Highs - The Globe and Mail
Jefferies Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $70 - 富途牛牛
Scotiabank Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
Citi reiterates Buy rating on BridgeBio stock ahead of key trial data - Investing.com Canada
Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com
BridgeBio Pharma (BBIO) Receives Buy Rating from Jefferies | BBIO Stock News - GuruFocus
Citi Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $67 - 富途牛牛
Jefferies Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - MSN
BridgeBio Pharma stock initiated with Buy rating at Jefferies on Attruby potential - Investing.com Canada
BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA - MSN
BridgeBio Pharma's BBP-418: A Promising Investment in Groundbreaking LGMD2I/R9 Therapy - AInvest
BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights - MSN
Helix shareholders to vote on BridgeBio Oncology merger on August 4 By Investing.com - Investing.com Nigeria
Helix shareholders to vote on BridgeBio Oncology merger on August 4 - Investing.com Australia
Cancer-Focused BridgeBio's $949M SPAC Deal Gets SEC Nod - Law360
BridgeBio Oncology's SPAC Merger Advances: SEC Clears Path for Novel Cancer Drug Development Platform - Stock Titan
BridgeBio Pharma stock hits 52-week high, reaching $45.53 By Investing.com - Investing.com South Africa
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bridgebio Pharma Inc 주식 (BBIO) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Kumar Neil | Chief Executive Officer |
Jul 01 '25 |
Sale |
42.54 |
40,000 |
1,701,400 |
975,686 |
VIKING GLOBAL INVESTORS LP | 10% Owner |
Jun 27 '25 |
Sale |
44.00 |
3,500,000 |
154,000,000 |
18,555,375 |
자본화:
|
볼륨(24시간):